Volume 14 Issue 2
Mar.  2023
Turn off MathJax
Article Contents
WANG Wei, ZHANG Yuelun, GAO Sihao, SONG Hongmei. Protocol for the Development of the Guidelines for the Genetic Diagnosis of Autoinflammatory Diseases in China[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 241-246. doi: 10.12290/xhyxzz.2023-0077
Citation: WANG Wei, ZHANG Yuelun, GAO Sihao, SONG Hongmei. Protocol for the Development of the Guidelines for the Genetic Diagnosis of Autoinflammatory Diseases in China[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 241-246. doi: 10.12290/xhyxzz.2023-0077

Protocol for the Development of the Guidelines for the Genetic Diagnosis of Autoinflammatory Diseases in China

doi: 10.12290/xhyxzz.2023-0077
Funds:

National Key Research and Development Program of China 2021YFC2702001

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-079

More Information
  • Corresponding author: SONG Hongmei, E-mail: songhm1021@126.com
  • Received Date: 2023-02-13
  • Accepted Date: 2023-02-14
  • Available Online: 2023-03-03
  • Publish Date: 2023-03-30
  • Autoinflammatory diseases (AIDs) were defined over 20 years ago, and since then, 56 monogenic AIDs have been discovered. Due to the overlapping symptoms, AIDs are prone to misdiagnosis and mistreatment. Different AIDs are characterized by distinct genetic variants, and some AIDs have shown unique genetic characteristics in the Chinese population. Currently, there is no evidence-based guideline for the genetic diagnosis of AIDs in China. To further standardize the early recognition and precision diagnosis of AIDs, it is urgently needed to develop evidence-based clinical practice guidelines on the genetic diagnosis of AIDs to provide scientific guidance for the clinical management of AIDs. The Chinese Pharmacists Association Rare Diseases Medication Working Committee and the Subspecialty Group of Immunology from the Society of Pediatrics of the Chinese Medical Association have jointly launched a protocol for the development of the Guidelines for the Genetic Diagnosis of Autoinflammatory Diseases in China, which was registered and written following WHO Handbook for Guideline Development with the help of nationwide multidisciplinary experts organized by the Department of Pediatrics, Peking Union Medical College Hospital. A formal document of the guidelines will be devised and published following the workflow of evidence-based guideline development. This paper introduces the Guidelines for the Genetic Diagnosis of Autoinflammatory Diseases in China, including its background, significance, objectives, target population, guideline users, guideline working group members, and the workflow of guideline development.
  • loading
  • [1] Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus Proposal for Taxonomy and Definition of the Autoinflamma-tory Diseases (AIDs): A Delphi Study[J]. Ann Rheum Dis, 2018, 77: 1558-1565. doi:  10.1136/annrheumdis-2017-212515
    [2] Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee[J]. J Clin Immunol, 2022. doi:  10.1007/s10875-022-01289-3.
    [3] Graham R, Mancher M, Miller WD, et al. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust[M]. Washington DC: National Academies Press, 2011.
    [4] Sinclair D, Isba R, Kredo T, et al. World Health Organization Guideline Development: An Evaluation[J]. PLoS One, 2013, 8: e63715. doi:  10.1371/journal.pone.0063715
    [5] Brouwers MC, Kerkvliet K, Spithoff K, et al. The AGREE Reporting Checklist: A Tool to Improve Reporting of Clinical Practice Guidelines[J]. BMJ, 2016, 352: i1152.
    [6] Chen Y, Yang K, Marušic A, et al. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement[J]. Ann Intern Med, 2017, 166: 128-132. doi:  10.7326/M16-1565
    [7] Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: A Critical Appraisal Tool for Systematic Reviews That Include Randomised or Non-Randomised Studies of Healthcare Interventions, or Both[J]. BMJ, 2017, 358: j4008.
    [8] Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials[J]. BMJ, 2011, 343: d5928. doi:  10.1136/bmj.d5928
    [9] Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: A Tool for Assessing Risk of Bias in Non-Randomised Studies of Interventions[J]. BMJ, 2016, 355: i4919.
    [10] Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies[J]. Ann Intern Med, 2011, 155: 529-536. doi:  10.7326/0003-4819-155-8-201110180-00009
    [11] Stang A. Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses[J]. Eur J Epidemiol, 2010, 25: 603-605. doi:  10.1007/s10654-010-9491-z
    [12] Rostom A, Dubé C, Cranney A, et al. Appendix D. Quality Assessment Forms[M]. Rockville (MD): Agency for Healthcare Research and Quality (US), 2004.
    [13] Institute of Health Economics (IHE). Quality Appraisal of Case Series Studies Checklist[EB/OL] (2016-03-02)[2023-02-13]. http://www.ihe.ca/research-programs/rmd/cssqac/cssqac-about.
    [14] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations[J]. BMJ, 2008, 336: 924-926. doi:  10.1136/bmj.39489.470347.AD
    [15] ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the Management of Autoinflammatory Diseases[J]. Ann Rheum Dis, 2015, 74: 1636-1644. doi:  10.1136/annrheumdis-2015-207546
    [16] Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, et al. Diagnostic Criteria for Cryopyrin-Associated Periodic Syndrome (CAPS)[J]. Ann Rheum Dis, 2017, 76: 942-947. doi:  10.1136/annrheumdis-2016-209686
    [17] Hansmann S, Lainka E, Horneff G, et al. Consensus Protocols for the Diagnosis and Management of the Hereditary Autoinflammatory Syndromes CAPS, TRAPS and MKD/HIDS: A German PRO-KIND Initiative[J]. Pediatr Rheumatol Online J, 2020, 18: 17. doi:  10.1186/s12969-020-0409-3
    [18] Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist[J]. Ann Rheum Dis, 2022, 81: 907-921. doi:  10.1136/annrheumdis-2021-221801
    [19] Cetin Gedik K, Lamot L, Romano M, et al. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI and AGS[J]. Ann Rheum Dis, 2022, 81: 601-613. doi:  10.1136/annrheumdis-2021-221814
    [20] Shinar Y, Ceccherini I, Rowczenio D, et al. ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the next-Generation Sequencing Era[J]. Clin Chem, 2020, 66: 525-536. doi:  10.1093/clinchem/hvaa024
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Article Metrics

    Article views (2158) PDF downloads(210) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return